The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | Less aggressive approaches in relapsed/refractory Hodgkin lymphoma
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, highlights areas of unmet need for patients with relapsed/refractory Hodgkin lymphoma (HL), including personalized, less aggressive approaches in the second-line setting, and potentially removing transplantation from the treatment approach for favorable patients with Hodgkin lymphoma. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
